Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China

Xinyue Zhang 1, Yue Lang 1, Lichao Sun 2, Weiguanliu Zhang 1, Weihong Lin 1 and Li Cui 1*

Abstract

Objective: To investigate the clinical characteristics and prognosis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis.

Methods: This retrospective study enrolled nineteen patients with anti-GABA-B receptor encephalitis. Clinical manifestations, radiological and electroencephalogram features, treatment and outcomes were collected and analyzed. The neurological function was evaluated according to the modified Rankin Scale (mRS).

Results: There were eleven patients in the favorable-prognosis group (mRS ≤ 2) and eight patients in the poor-prognosis group (mRS > 2). In the favorable-prognosis group, clinical symptoms included memory deterioration (n = 10; 90.9%), epileptic seizures (n = 9; 81.8%), psychiatric disorders (n = 9; 81.8%), and conscious disturbance (n = 5; 45.5%); magnetic resonance imaging (MRI) indicated an involvement of the limbic system in three (27.3%) cases in this group. Lung cancer was detected in one patient (9.1%). After an average follow-up period of 11.7 months, four (36.4%) patients were cured, and seven (63.6%) patients showed significant improvements. In the poor-prognosis group, all patients presented with memory deterioration, epileptic seizures, psychiatric disorders, and conscious disturbance; five (62.5%) patients had convulsive status epilepticus, and five (62.5%) patients developed respiratory failure; MRI indicated an involvement of the limbic system in seven (87.5%) cases. Malignant tumors were detected in five (62.5%) patients. After an average follow-up period of 14.8 months, seven (87.5%) patients died and one (12.5%) patient remained dependent in daily life.

Conclusions: The clinical manifestations of anti-GABA-B receptor encephalitis include epileptic seizures, cognitive impairment and psychiatric disorders. Patients with convulsive status epilepticus or respiratory failure have poor outcomes. In anti-GABA-B receptor encephalitis, limbic system involvement is associated with a poor prognosis in and radiological examinations can reflect disease progression. Early diagnosis and appropriate treatment should be highlighted.

Keywords: Anti-gamma-aminobutyric acid-B receptor encephalitis, Limbic encephalitis, Autoantibody, Convulsive status epilepticus, Prognosis
**Introduction**

Limbic encephalitis (LE) refers to an acute or subacute inflammatory disorder of the central nervous system that predominantly affects the structures of the limbic system, such as the hippocampus, amygdaloid nucleus, insula and cingulate gyrus [1]. Clinically, LE is characterized by the impairment of recent memory, mental and behavioral disorders and epileptic seizures. Previously, LE was considered to be a paraneoplastic disease related to lung cancer, testicular cancer and some other tumors; thus, it was also known as paraneoplastic limbic encephalitis (PLE) [2, 3]. With the discovery of antibodies to onconeural intracellular antigens, such as Hu, PNMA2 (Ma2/Ta) and CV2/CRMP5, LE has been recognized as an autoimmune disease. Subsequently, antibodies against neuronal surface antigens, such as the gamma-aminobutyric acid-B (GABA-B) and N-methyl-D-aspartate (NMDA) receptors have been discovered and the cases of LE that are associated with these antibodies have been classified as a new-type limbic encephalitis or autoimmune synaptic encephalitis [4, 5].

Anti-GABA-B receptor encephalitis is an autoimmune encephalitis caused by antibodies to GABA-B receptor in the limbic system. This form of the disease accounts for approximately 5% of all cases of LE [4]. Recently, anti-GABA-B receptor encephalitis has gained great attention and an increasing number of cases have been reported in western countries. However, anti-GABA-B receptor encephalitis has rarely been studied in the Chinese population, and the relevant clinical and prognostic features in this region remain poorly understood. This study aimed to investigate the clinical characteristics and prognosis of anti-GABA-B receptor encephalitis in Northeast China.

**Materials and methods**

**Patients**

This retrospective study enrolled nineteen patients that had been diagnosed with anti-GABA-B receptor encephalitis at the Department of Neurology of the First Hospital of Jilin University between September 2014 and August 2017. The inclusion criteria were as follows: 1) acute or subacute onset (clinical course < 3 months) with progressive symptoms; 2) clinical symptoms consistent with the diagnosis of LE; 3) cerebrospinal fluid (CSF) examination results of slightly increased lymphocyte count or normal leucocyte count; 4) brain magnetic resonance imaging (MRI) revealed normal results or demonstrated abnormal signals in unilateral or bilateral limbic system; 5) anti-GABA-B receptor antibodies were positive in the serum and/or CSF; and 6) there were no infectious, traumatic, toxic, metabolic, intracranial neoplastic or demyelinating diseases.

This study was approved by the local Ethics Committee. Written informed consent was obtained from each participant.

**Data collection**

The data, including clinical manifestations, radiological and electroencephalogram (EEG) features, laboratory examination results, treatment and outcomes, were collected and analyzed. The neurological function was evaluated according to modified Rankin Scale (mRS), and the patients were divided into two groups: a favorable-prognosis group (mRS ≤ 2) and a poor-prognosis group (mRS > 2) [6]. All of the patients underwent laboratory examinations for anti-autoimmune encephalitis antibodies, routine CSF testing, biochemical CSF testing, and EEG. Antibodies to the GABAB receptor, NMDA receptor, AMPA receptor, LGI1 and CASPR2 and classic paraneoplastic autoantibodies (anti-Hu, −Yo, −Ri, −CV2/CRMP5, −amphiphysin and - Ma2/Ta) in serum and/or CSF samples were measured using indirect immunofluorescence assay (Euroimmun AG, Lübeck, Germany). The titers of antibodies were categorized as slightly positive (+; < 1:10), positive (++; < 1:100), and strongly positive (+++; ≥1:100). Eighteen patients underwent brain MRI and pulmonary computed tomography (CT). Two patients underwent positron emission tomography-computed tomography (PET-CT), and two patients underwent pathological biopsy of the pulmonary lesion. Fifteen patients received immunomodulating therapy after the diagnosis of anti-GABA-B receptor encephalitis.

**Statistical analysis**

SPSS 24.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analyses. Continuous variables were expressed as the mean ± standard deviation (SD) and compared using Student’s t test. Categorical values were expressed as frequencies (percentage, %) and compared using Fisher’s exact test. P values of less than 0.05 were considered statistically significant and P values of less than 0.01 were considered highly significant.

**Results**

**Clinical characteristics**

Ten males and nine females, with an average age of 58.63 ± 11.43 years (range 23–79 years), were included in this study. Eighteen patients were Han Chinese and one patient was Chinese Korean. The symptom duration ranged from 14 h to 3 months. There were eleven patients in the favorable-prognosis group (mRS ≤ 2) and eight patients in the poor-prognosis group (mRS > 2). There was no significant difference in patients’ age between the two groups (P = 0.305).

In the favorable-prognosis group, clinical symptoms included memory deterioration (n = 10; 90.9%), epileptic seizures (n = 9; 81.8%), psychiatric disorders (n = 9; 81.8%), and conscious disturbance (n = 5; 45.5%); In the poor-prognosis group, all of the patients presented with memory deterioration, epileptic seizures, psychiatric...
disorders, and conscious disturbance; five (62.5%) patients had convulsive status epilepticus, and five (62.5%) patients developed respiratory failure. Statistical analyses show a significant difference in the occurrence of convulsive status epilepticus and respiratory failure ($P = 0.005$). The detailed clinical characteristics of the nineteen patients with anti-GABA-B receptor encephalitis are summarized in Table 1.

**Radiological examinations**

In the favorable-prognosis group, MRI revealed an involvement of the limbic system in three (27.3%) cases; the lesions were small and the distribution was restricted to the temporal lobe and hippocampus. In the poor-prognosis group, MRI revealed involvement of the limbic system in seven (87.5%) cases. In these cases, the lesions were extensively distributed in the temporal lobe, insula and hippocampus. The lesions appeared hypointense on T1-weighted imaging and hyperintense on T2-weighted, fluid attenuated inversion recovery (FLAIR), and diffusion-weighted imaging. Statistical analysis shows that an involvement of the limbic system was more prevalent in the poor-prognosis group ($P = 0.025$). The detailed results are presented in Table 2 and Table 3.

PET-CT revealed a peripheral lung cancer with lymphatic metastasis in one patient in the favorable-prognosis group. In the poor-prognosis group, lung cancer was observed in four patients and a malignant mediastinal tumor was discovered in one patient. There was a significant difference in the occurrence of malignant tumors between the two groups ($P = 0.041$). The detailed results are summarized in Table 4.

**EEG examinations**

In the favorable-prognosis group, epileptic abnormal discharges were noted in seven cases, including focal seizures in five cases and non-convulsive status epilepticus in three cases; nonspecific irregular slow waves were observed in two cases, and the EEG results were normal in two cases. In the poor-prognosis group, epileptic abnormal discharges were observed in seven cases, including focal seizures or focal status epilepticus in six cases and non-convulsive status epilepticus in one case; nonspecific irregular slow waves were observed in one case. The detailed EEG results are presented in Table 3.

**Laboratory tests**

All patients were positive for serum anti-GABA-B receptor antibodies. The titers of anti-GABA-B receptor antibodies in the CSF ranged from slight positivity to strong positivity. There was no significant difference in the CSF antibody titer between the two groups ($P = 0.442$). In the favorable-prognosis group, one case showed positivity for the anti-NMDAR antibody. In the poor-prognosis group, anti-Hu antibody positivity in the serum and CSF was observed in two patients, and anti-CV2/CRMP5 antibody positivity was observed in the serum and CSF in one patient. There was no significant difference in the observation of anti-neuron antibody positivity between the two groups ($P = 0.262$).

The CSF appearance was colorless and clear in all patients. The pressure ranged from 70 mmH$_2$O to 300 mmH$_2$O. In the favorable-prognosis group, an elevated leukocyte count was found in six cases and an elevated protein level was noted in three cases; in the poor-prognosis group, an elevated leukocyte count was noted in seven cases and an elevated protein level was noted in two cases. There was no significant difference in the leukocyte count ($P = 0.177$) or the protein level ($P > 0.05$) between the two groups. The detailed results are presented in Table 5.

**Treatment and prognosis**

In the favorable-prognosis group, ten patients underwent immunomodulating therapy, four patients were treated with methylprednisolone (120–1000 mg), four patients were treated with intravenous immunoglobulin (IVIG; 0.4 g/kg/day), two patients received combined methylprednisolone and IVIG treatment, and no specific treatment was performed in one patient. After an average follow-up period of 11.7 months (range, 2–27 months), four (36.4%) patients were cured, and seven (63.6%) patients showed significant improvement. After treatment with antiepileptic drugs, the epileptic symptoms were well controlled in all patients.

| Table 1 | Clinical characteristics of nineteen patients with anti-GABA-B receptor encephalitis |
|---------|--------------------------------------------------------------------------------------------------|
| Characteristics | Favorable-prognosis group ($n = 11$) | Poor-prognosis group ($n = 8$) |
| Gender (male/female) | 5/6 | 5/3 |
| Age (years) | 56.27 ± 13.76 | 61.87 ± 6.66 |
| Limbic system symptoms | 10 (90.9%) | 8 (100%) |
| Epilepsy/Convulsive status epilepticus | 9 (81.8%)/0 (0%) | 8 (100%)/5 (62.5%) |
| Psychiatric disorder | 9 (81.8%) | 8 (100%) |
| Conscious disturbance | 5 (45.5%) | 8 (100%) |
| Respiratory failure | 0 (0%) | 5 (62.5%) |
Table 2 Radiological features of eighteen patients with anti-GABA-B receptor encephalitis

| Involvement of limbic system on MRI | Favorable-prognosis group (n = 10) | Poor-prognosis group (n = 8) | Total (n = 18) |
|------------------------------------|-------------------------------------|------------------------------|---------------|
| Involvement of limbic system on MRI | 3 (30.0%)                           | 7 (87.5%)                    | 10 (55.6%)    |
| No involvement of limbic system on MRI | 7 (70.0%)                           | 1 (12.5%)                    | 8 (44.4%)     |
| Total                              | 10 (100%)                           | 8 (100%)                     | 18 (100%)     |

P = 0.025 in Fisher’s exact test

Table 3 Initial symptoms, magnetic resonance imaging and electroencephalogram of nineteen patients with anti-GABA-B receptor encephalitis

| Case No. | Initial symptoms | Magnetic resonance imaging | Electroencephalogram |
|----------|------------------|----------------------------|-----------------------|
| Favorable-prognosis group |
| 1 | Seizures | Abnormal signals in the right temporal lobe | Focal seizures followed by non-convulsive status epilepticus |
| 2 | Seizures, psychiatric abnormalities | Abnormal signals in the bilateral hippocampus and frontal lobes | Focal seizures originating from the temporal area |
| 3 | Seizures, psychiatric abnormalities | Normal | Non-convulsive status epilepticus manifesting as periodic lateralized epileptiform discharges |
| 4 | Seizures, psychiatric abnormalities | Not available | Normal |
| 5 | Seizures, psychiatric abnormalities | Leukoaraiosis | Focal seizures originating from the left temporal area |
| 6 | Seizures, cognitive impairment | Normal | Normal |
| 7 | Seizures | Normal | Sharp and sharp-slow waves originating from the right frontal-temporal area |
| 8 | Seizures, psychiatric abnormalities, cognitive impairment | Abnormal signals in the left temporal lobe | Irregular slow waves originating from the frontal-temporal area |
| 9 | Seizures | Normal | Non-convulsive status epilepticus originating from the frontal midline area |
| 10 | Memory impairment | Leukoaraiosis and multiple lacunar infarctions | Scattered slow waves |
| 11 | Seizures | Normal | Focal seizures originating from the right frontal area |
| Poor-prognosis group |
| 12 | Seizures | Abnormal signals in the right temporal lobe | Focal seizures originating from the left temporal-occipital area |
| 13 (primary) | Seizures | Abnormal signals in the left thalamus, insula, temporal lobe, hippocampus, and bilateral frontal-parietal lobes | Focal status epilepticus originating from the left temporal area |
| 13 (recurrence) | Seizures | Abnormal signals in the right hippocampus and temporal lobe | Focal status epilepticus originating from the right temporal area |
| 14 | Diarrhea, seizures | White matter demyelination and multiple lacunar infarctions | Slow waves originating from the frontal midline area |
| 15 | Seizures | Abnormal signals in the left temporal lobe | Focal seizures originating from the frontal area |
| 16 | Seizures | Abnormal signals in the right hippocampus | Focal status epilepticus originating from the right temporal area |
| 17 | Seizures | Abnormal signals in the bilateral hippocampus | Focal seizures originating from the left temporal area |
| 18 | Seizures | Abnormal signals in the bilateral hippocampus and insula | Non-convulsive status epilepticus originating from the frontal area |
| 19 | Seizures, confusion | Abnormal signals in the left hippocampus | Focal status epilepticus originating from the left temporal area |
In the poor-prognosis group, one patients were treated with methylprednisolone and succumbed to respiratory failure; no specific treatment was performed in three patients, all of whom succumbed to respiratory failure; four patients received combined methylprednisolone and IVIG treatment, all of whom had concomitant lung cancer, and three of these patients succumbed to lung cancer progression. Overall, after an average follow-up period of 14.8 months, seven (87.5%) patients had died and one (12.5%) patient remained dependent on care in daily life. In five patients, the epilepsy responded poorly to antiepileptic drugs. The detailed clinical profiles are summarized in Table 5.

**Table 4** Concurrence of malignant tumors and anti-GABA-B receptor encephalitis

| Group                     | Favorable-prognosis group (n = 11) | Poor-prognosis group (n = 8) | Total (n = 19) |
|---------------------------|------------------------------------|-----------------------------|----------------|
| Accompanied malignant tumor | 1 (9.1%)                           | 5 (62.5%)                   | 6 (31.6%)       |
| No malignant tumor         | 10 (90.9%)                         | 3 (37.5%)                   | 13 (68.4%)      |
| Total                      | 11 (100%)                          | 8 (100%)                    | 19 (100%)       |

*P = 0.041 in Fisher’s exact test*

In the poor-prognosis group, one patients were treated with methylprednisolone and succumbed to respiratory failure; no specific treatment was performed in three patients, all of whom succumbed to respiratory failure; four patients received combined methylprednisolone and IVIG treatment, all of whom had concomitant lung cancer, and three of these patients succumbed to lung cancer progression. Overall, after an average follow-up period of 14.8 months, seven (87.5%) patients had died and one (12.5%) patient remained dependent on care in daily life. In five patients, the epilepsy responded poorly to antiepileptic drugs. The detailed clinical profiles are summarized in Table 5.

**Discussion**

Anti-GABA-B receptor encephalitis is a rare autoimmune LE [7]. As previously reported, the average onset age of anti-GABA-B receptor encephalitis is 60–70 years, with no obvious gender preference. The clinical symptoms of this disease include epileptic seizures, memory impairment, anxiety, conscious disturbance, and disorientation [7]. In some cases, anti-GABA-B receptor encephalitis can also manifest as oblique clonus, myoclonus, Stiffman syndrome, and cerebellar ataxia. Notably, most patients with anti-GABA-B receptor encephalitis have concomitant small-cell lung cancer [7–11]. Until now, anti-GABA-B receptor encephalitis has rarely been reported in the Chinese population. In the current study, we retrospectively analyzed the clinical characteristics and prognosis of nineteen patients with anti-GABA-B receptor encephalitis in Northeast China. In the literature, elderly age is associated with poor prognosis in this disease. Thus, the current study has added to the known symptom spectrum of this disease.

Although epileptic seizures are the major clinical manifestation of anti-GABA-B receptor encephalitis, the EEG features are usually non-specific. In the favorable-prognosis group of this study, epileptic abnormal discharges were noted in seven cases. Such abnormalities include ictal or interictal sharp-slow waves and spikeslow waves, more than half of which showed focal seizures that originated in frontal and temporal regions.
| Case No. | Anti-GABA-B receptor antibodies | Other antibodies | CSF routine | Treatment | Follow-up period (months) | Outcomes | Initial mRS on admission | Follow-up mRS |
|----------|----------------------------------|------------------|-------------|-----------|--------------------------|----------|--------------------------|--------------|
| **Favorable-prognosis group** | | | | | | | | |
| 1 | + | + | − | − | 8 | 0.36 | + | 70 | MP | LEV | 18 | Cured | 5 | 0 |
| 2 (primary) | ++ | ++ | − | − | 18 | 0.57 | + | 30 | IVIG | LEV | | | | |
| 2 (recurrence) | + | + | − | − | 18 | 0.74 | − | 7 | IVIG+MP | − | 17 | Improved | 4 | 1 |
| 3 | +++ | +++ | − | − | 5 | 0.43 | − | 30 | IVIG+MP | − | 2 | Improved | 5 | 1 |
| 4 | ++ | ++ | − | − | 103 | 0.53 | − | 16 | IVIG | − | 27 | Improved | 2 | 1 |
| 5 | ++ | ++ | − | − | 42 | 0.39 | + | 18 | IVIG | OXC | 20 | Cured | 5 | 0 |
| 6 | + | + | − | − | 4 | 0.44 | − | 15 | IVIG+MP | VPA + LEV | 8 | Improved | 2 | 1 |
| 7 | + | + | − | − | 19 | 0.34 | − | 22 | IVIG | − | 5 | Improved | 4 | 1 |
| 8 | + | + | – | NMDAR+ | 7 | 0.39 | − | − | − | − | 3 | Improved | 5 | 1 |
| 9 | + | + | − | − | 8 | 0.33 | − | 35 | IVIG+MP | − | 3 | Improved | 5 | 1 |
| 10 | + | + | − | − | 34 | 1.09 | − | 17 | IVIG | − | 2 | Improved | 2 | 1 |
| 11 (primary) | ++ | + | − | − | 20 | 0 | + | 29 | MP | − | 5 | Improved | 2 | 0 |
| 11 (recurrence) | + | + | − | − | 6 | 0.24 | − | − | LEV | − | 27 | Cured | 3 | 0 |
| **Poor-prognosis group** | | | | | | | | |
| 12 | + | + | Hu+ | − | 43 | 0.39 | + | 15 | IVIG | − | 9 | Death | 4 | 6 |
| 13 (primary) | ++++ | ++++ | CV2/CRMP5++ | CV2/CRMP5+++ | 9 | 0.63 | + | 15 | IVIG+MP | − | 13 | Death | 5 | 6 |
| 13 (recurrence) | + | + | CV2/CRMP5+ | CV2/CRMP5+ | 9 | 0.63 | + | 8 | IVIG+MP | − | 27 | Death | 5 | 6 |
| 14 | ++++ | ++++ | Hu+ | Hu+ | 96 | 0.37 | + | − | − | − | 27 | Death | 5 | 6 |
| 15 | ++++ | ++ | − | − | 7 | 0.37 | + | 12 | IVIG+MP | − | 25 | Death | 5 | 6 |
| 16 | + | + | − | − | 13 | 0.39 | + | − | − | − | 12 | Death | 5 | 6 |
| 17 | ++ | ++ | − | − | 21 | 0.49 | + | 13 | IVIG+MP | − | 20 | Death | 5 | 6 |
| 18 | + | + | − | − | 13 | 0.29 | + | − | − | − | 3 | Death | 5 | 6 |
| 19 | + | + | − | − | 31 | 0 | + | 5 | IVIG+MP | − | 9 | Unchanged | 5 | 5 |

CSF, cerebrospinal fluid; WBC, white blood cell; mRS, modified Rankin scale; NMDAR, anti-N-methyl-D-aspartate receptor antibody; Hu, anti-Hu antibody; CV2/CRMP5, anti-CV2/CRMP5 antibody; MP, methylprednisolone; IVIG, intravenous immunoglobulin; LEV, levetiracetam; OXC, oxcarbazepine; VPA, valproic acid; CBZ, carbamazepine
the poor-prognosis group, seven patients had epileptic abnormal discharges, and six of these manifested as focal seizures or focal status epilepticus originating in frontal and temporal regions. Notably, four patients had non-convulsive status epilepticus. Non-convulsive status epilepticus refers to an extreme cerebral dysfunction characterized by continuous or repeated epileptic waves over 30 min. Previous studies have found that elderly patients with non-convulsive status epilepticus had a poor prognosis, which may be related to the more serious clinical severity and nosocomial infection [19]. Recently, the relationship between anti-GABA-B receptor encephalitis and non-convulsive status epilepticus has gained more attention, while the correlation between non-convulsive status epilepticus and clinical prognosis remains unclear. In our study, there was no significant difference in the occurrence of non-convulsive status epilepticus between the two groups, indicating that non-convulsive status epilepticus is not correlated with the prognosis of anti-GABA-B receptor encephalitis.

Since the discovery of the NMDAR antibody in 2007, there have been several reports of novel anti-neuronal antibodies related to autoimmune encephalitis. These antibodies can be divided into two categories: 1) antibodies against neuronal surface receptors, including anti-NMDAR antibodies, anti-GABA-B receptor antibodies, anti-LGI-1 antibodies, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies, and anti-voltage-gated potassium channels (VGKC) antibodies; and 2) antibodies against intracellular antigens, such as anti-Hu antibodies and anti-Ma2 antibodies. Generally, autoantibodies have strong specificity and diagnostic values. Co-expression of multiple antineuronal autoantibodies is rare in autoimmune encephalitis, but is relatively more common in anti-GABA-B receptor encephalitis with an incidence of 7%~40% [7, 8, 11, 12]. In a previous study involving 20 patients with anti-GABA-B receptor encephalitis, positivity for multiple antibodies was observed in seven (35%) cases; five patients with concomitant small-cell lung cancer were found to be positive for the paraneoplastic antibodies SOX1 and Ri/ANNA2, and in two patients that did not have small-cell lung cancer the GAD65 and anti-NMDAR antibodies were detected. In our study, although positivity for the anti-NMDAR antibody, anti-CV2/CRMP5 antibody, and anti-Hu antibody were detected in a few cases, there was no significant difference in the autoantibodies that were detected between the two groups. Further research is needed to understand the clinical significance of these paraneoplastic antibodies in anti-GABA-B receptor encephalitis [8].

The radiological features of anti-GABA-B receptor encephalitis are non-specific and may be negative in some patients [7, 9, 12]. We found that involvement of the limbic system, as determined through MRI, was more common in the poor-prognosis group than in the favorable prognosis group. Thus, we speculate that MRI manifestations can reflect the disease progression in this disease, to a certain degree. For instance, the patient in Case two presented with a 22-day history of seizures and balderdash, in which the brain MRI results revealed hyperintensities in the bilateral hippocampus and right frontal lobe; the patient was clinically and radiologically improved after gamma globulin treatment (Fig. 1). The patient in Case eight presented with memory deterioration, and the brain MRI results revealed a hyperintensity in the left hippocampus; in the following 1 month after admission, the symptom was aggravated, and repeated MRI showed that the lesion had grown (Fig. 2). The initial MRI in Case nineteen showed abnormal signals in the left hippocampus. And, although, the patient was clinically and radiologically improved after treatment with gamma globulin and methylprednisolone, 3 months after discharge, the patient was readmitted due to memory deterioration, and repeated brain MRI showed an enlargement of the lesion (Fig. 3).

The optimal treatment for anti-GABA-B receptor encephalitis remains debated. Mainstream therapeutic strategies include immunomodulating therapy, immunosuppressive therapy, tumor resection, and chemotherapy. Current immunotherapies include IVIG, plasmapheresis,

![Fig. 1 Magnetic resonance imaging of Case two.](image-url)
corticosteroids, and cyclophosphamide. Previous evidence showed early immunotherapy could significantly improve the clinical prognosis and lower the mortality [20]. However, in our study, there was no significant difference in the effects of immunotherapy between two groups. Further clinical trials are required to determine the definitive efficacy of immunotherapy. Additionally, epileptic seizures in patients with anti-GABA-B receptor encephalitis are usually refractory, and the treatment is challenging [21]. When conventional antiepileptic drugs provide no benefits, immunotherapy may be helpful in the treatment of the epileptic symptoms [22]. In our study, epilepsy was well controlled in the favorable-prognosis group as well as the poor-prognosis group following immunotherapy. Therefore, we recommend immunotherapy as the first-line treatment for anti-GABA-B receptor encephalitis. In recent years, the concept of autoimmune limbic encephalitis (ALE) has been gradually accepted. This term refers to new-onset seizures in the context of acute or subacute neurocognitive impairment. As mentioned above, although limbic encephalitis can present with a variety of neuropsychiatric symptoms, seizures remain the most common symptoms and often progress to refractory ALE. Beyond the use of antiepileptic drugs and treatment for potential tumors, there is no effective treatment for ALE [20]. Previous studies have shown that immunomodulatory therapy may be an effective treatment when epileptic seizures respond poorly to conventional antiepileptic drugs [21]. These findings further support the idea that immunomodulatory therapy should be the first-line treatment for anti-GABA-B receptor encephalitis. In this study, the patients were treated with antiepileptic drugs, according to individual seizure type and EEG results. In the favorable-prognosis group, the seizures were well controlled.

The prognosis of anti-GABA-B receptor encephalitis remains unclear. Generally, early diagnosis and timely intervention are associated with a better prognosis, although some patients may die due to the poor response to treatment [23]. In this study, we found that patients with status epilepticus, respiratory failure and/or an involvement of the limbic system had worse outcomes than patients without these features. We speculate that these factors may be predictors of poor prognosis.

**Conclusions**

Anti-GABA-B receptor encephalitis clinically manifests as epileptic seizures, cognitive impairment and psychiatric disorders. Patients with convulsive status epilepticus or respiratory failure have poor outcomes, and the involvement of the limbic system is associated with a poor prognosis. Radiological examinations can reflect the disease progression and prompt diagnosis and appropriate treatment should be emphasized.
Abbreviations
ALE: autoimmune limbic encephalitis; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2: contactin-associated protein-like 2; CBZ: carbamazepine; CSF: cerebrospinal fluid; CT: computed tomography; CRMP5: collapsin response mediator protein 5; EEG: electroencephalogram; FLAIR: fluid attenuated inversion recovery; GABA-B: gamma-aminobutyric acid-B; IVIG: intravenous immunoglobulin; LE: limbic encephalitis; LEV: levetiracetam; LGI1: leucine-rich glioma-inactivated 1; MP: methylprednisolone; MRI: magnetic resonance imaging; mRS: modified Rankin Scale; NMDA: N-methyl-D-aspartate; NMDAR: N-methyl-D-aspartate receptor; OXC: oxcarbazepine; PET-CT: positron emission tomography–computed tomography; PLE: paraneoplastic limbic encephalitis; SD: standard deviation; VGC: voltage-gated potassium channels; VPA: valproic acid; WBC: white blood cell

Acknowledgements
We would like to thank all of the patients who participated in this study.

Authors’ contributions
XYZ collected and analyzed the clinical data and drafted the manuscript. YL, LC and WL reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data used and/or analyzed during the study is available on request from the First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, Jilin, China.

Ethics approval and consent to participate
The study was approved by the First Hospital of Jilin University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Neurology, Neuroscience Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, Jilin, China. 2. Department of Emergency, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, Jilin, China.

Received: 17 April 2019 Accepted: 22 December 2019

References
1. Vincent A. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127(Pt 3):701–12.
2. Correllis JAN, Goldberg GJ, Norton AR. “Limbic encephalitis” and its association with carcinoma. Brain. 1968;91(3):481–96.
3. Bakheit AM, Kennedy PG, Behan PO. Paraneoplastic limbic encephalitis: clinico-pathological correlations. J Neurol Neurosurg Psychiatry. 1990;53(12):1084–8.
4. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitides and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–89.
5. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30(17):5866–75.
6. Van Swieten J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1989;20(6):828.
7. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67–76.
8. Höftberger R, Tituber MJ, Sabater L, et al. Encephalitides and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81(17):1500–6.
9. Boronat A, Sabater L, Saiz A, et al. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795.
10. Jarius S, Steinmeyer F, Knobel A, et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol. 2013;256(1–2):94–6.
11. Jeffery OJ, Lennon VA, Pittcock SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology. 2013;81(10):882.
12. Dogan Onugoren M, Deurtzborcher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2014;86(9):965–72.
13. Kim TJ, Lee ST, Shin JW, et al. Clinical manifestations and outcomes of the treatment of patients with GABA B encephalitis. J Neuroimmunol. 2014;270(1–2):45–50.
14. Serafini A, Lukas RV, Vanihaerents S, et al. Paraneoplastic epilepsies. Epilepsy Behavior E & B. 2016;61:51–8.
15. Mann EO, Kohl MM, Paulsen O. Distinct roles of GABA(a) and GABA(B) receptors in balancing and terminating persistent cortical activity. J Neurosci. 2009;29(23):7513–8.
16. Gelow J, Krue M, Yadav V, et al. Apical ballooning resulting from limbic encephalitis. Am J Med. 2009;122(6):583–6.
17. Mesulam MM, Mufson EJ. Insula of the old world monkey: III. efferent cortical output and comments on function. J Comp Neurol. 1982;212(1):38–52.
18. Loftspring MC, Eric L, Lindsey W, et al. GABAB encephalitis: a fifty-two-year-old man with seizures, Dysautonomia, and acute heart failure. Case Reports Neurol Med. 2015;2015:812035.
19. Labar D, Barrera J, Solomon G, et al. Nonconvulsive status Epilepticus in the elderly: a case series and a review of the literature. J Epilepsy. 1998;11(2):74–8.
20. Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391–419.
21. Vigevano F. Immuno- and antiinflammatory therapies in epileptic disorders. Epilepsia. 2011;52(s3):45–51.
22. Dubey D, Konikkara J, Modur PN, et al. Effectiveness of multimodality treatment for autoimmune limbic epilepsy. Epileptic Disorders. 2015;16(4):494–9.
23. Mundiyaparupath S, Jarius S, Probst C, et al. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259(1–2):88–91.